title: Loss of nuclear prothymosin-α expression is associated with disease progression in human superficial bladder cancer.
abstract: In this paper, we report a study on the clinical relevance of prothymosin-α expression and its correlation with intratumoral Foxp3(+) and CD8(+) lymphocytes (Foxp3(+)TIL and CD8(+)TIL) in bladder cancer patients. We used immunohistochemical staining for prothymosin-α, Foxp3, and CD8 on 101 tumor specimens harvested by endoscopic resection. The results were correlated with clinicopathological variables and clinical outcome in bladder cancer patients, particularly in 73 patients with superficial disease, using the log-rank test and Cox proportional hazard model. Overall, of the tumors, 30 % were negative, 34 % showed nuclear, and 37 % showed cytoplasmic prothymosin-α expression. Foxp3(+)TILs were detected in 11 % of patients (nonnuclear vs. nuclear, p = 0.096). Patients with a history of urothelial carcinoma have a higher frequency of nonnuclear prothymosin-α expression than those without (p = 0.016, chi-square test). By univariate and multivariate analyses of cases with superficial disease, grade and stage were identified as independent predictors for recurrence-free survival (p = 0.016 and 0.016, respectively). Higher stage and nonnuclear prothymosin-α expression independently predict shorter progression-free survival (p = 0.006 and 0.043, respectively). The presence of Foxp3(+)TILs was significantly associated with disease progression by univariate analysis (p = 0.022), but not by multivariate analysis (p = 0.147). In vitro assays showed that J82 cells which express ectopically nuclear prothymosin-α exhibit higher growth rate and secrete less TGF-β1 than those with cytoplasmic expression or control cells. Altogether, prothymosin-α expression is a determinant of disease progression in superficial bladder cancer. Foxp3(+)TILs tend to be found more often in bladder cancer with nonnuclear prothymosin-α expression. Future study is required to unravel their interaction.
authors.affiliation: Department of Urology, College of Medicine and Hospital, National Cheng Kung University, #138, Sheng-Li Road, Tainan, 70403, Taiwan, youh@mail.ncku.edu.tw.
authors.forename: Yuh-Shyan
authors.initials: YS
authors.lastname: Tsai
authors.forename: Yeong-Chin
authors.initials: YC
authors.lastname: Jou
authors.forename: Chun-Liang
authors.initials: CL
authors.lastname: Tung
authors.forename: Chang-Te
authors.initials: CT
authors.lastname: Lin
authors.forename: Cheng-Huang
authors.initials: CH
authors.lastname: Shen
authors.forename: Syue-Yi
authors.initials: SY
authors.lastname: Chen
authors.forename: Hsin-Tzu
authors.initials: HT
authors.lastname: Tsai
authors.forename: Chen-Li
authors.initials: CL
authors.lastname: Lai
authors.forename: Chao-Liang
authors.initials: CL
authors.lastname: Wu
authors.forename: Tzong-Shin
authors.initials: TS
authors.lastname: Tzai
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D002295:Carcinoma, Transitional Cell / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D002467:Cell Nucleus / Q000378:metabolism; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D051858:Forkhead Transcription Factors / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D008297:Male; D011379:Prognosis; D016016:Proportional Hazards Models; D011498:Protein Precursors / Q000032:analysis / Q000096:biosynthesis*; D013947:Thymosin / Q000031:analogs & derivatives* / Q000032:analysis / Q000096:biosynthesis; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D011498:Protein Precursors; C040782:prothymosin alpha; D013947:Thymosin
references.citation: Eur Urol. 2011 Jun;59(6):997-1008
references.pmid: 21458150
references.citation: Urology. 2006 Feb;67(2):294-9
references.pmid: 16461079
references.citation: Nat Rev Cancer. 2005 Aug;5(8):615-25
references.pmid: 16034368
references.citation: Life Sci. 1997;61(21):2091-101
references.pmid: 9395250
references.citation: Urol Oncol. 2013 Nov;31(8):1806-11
references.pmid: 22609059
references.citation: J Urol. 1972 Apr;107(4):607-9
references.pmid: 5014367
references.citation: Urology. 2009 Oct;74(4):951-7
references.pmid: 19679339
references.citation: Urology. 2009 Jan;73(1):188-92
references.pmid: 18692879
references.citation: J Urol. 2007 Jan;177(1):353-8
references.pmid: 17162090
references.citation: Exp Cell Res. 2000 May 25;257(1):152-61
references.pmid: 10854063
references.citation: Urol Oncol. 2012 Sep;30(5):680-7
references.pmid: 21420334
references.citation: Cancer Immunol Immunother. 2006 Oct;55(10):1247-57
references.pmid: 16453152
references.citation: Cell Death Differ. 2010 Nov;17(11):1760-72
references.pmid: 20467443
references.citation: Int J Immunopharmacol. 1991;13(8):1059-65
references.pmid: 1814846
references.citation: BJU Int. 2011 Nov;108(10):1672-8
references.pmid: 21244603
references.citation: FEBS Lett. 2000 Feb 11;467(2-3):150-4
references.pmid: 10675528
references.citation: J Cell Physiol. 2000 Feb;182(2):256-68
references.pmid: 10623890
references.citation: Eur Urol. 2011 Jun;59(6):1009-18
references.pmid: 21454009
references.citation: J Histochem Cytochem. 2008 Nov;56(11):1023-31
references.pmid: 18711212
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Nat Rev Cancer. 2005 Sep;5(9):713-25
references.pmid: 16110317
references.citation: Eur Urol. 2011 Apr;59(4):584-94
references.pmid: 21269756
references.citation: Eur J Surg Oncol. 2007 Mar;33(2):195-201
references.pmid: 17046193
references.citation: Kidney Int. 2005 May;67(5):1710-22
references.pmid: 15840017
references.citation: Cancer Immunol Immunother. 1995 Jun;40(6):410-8
references.pmid: 7543022
references.citation: FEBS Lett. 1999 May 21;451(2):118-24
references.pmid: 10371150
references.citation: Eur J Cancer. 1993;29A(6):893-7
references.pmid: 8387320
references.citation: Nat Commun. 2013;4:1906
references.pmid: 23695700
references.citation: Cancer Immun. 2007 Jun 26;7:10
references.pmid: 17591743
references.citation: Mol Immunol. 2009 Feb;46(5):784-92
references.pmid: 18976813
references.citation: Science. 2003 Jan 10;299(5604):223-6
references.pmid: 12522243
references.citation: J Interferon Cytokine Res. 1995 Aug;15(8):731-7
references.pmid: 8528946
references.citation: Proc Natl Acad Sci U S A. 1987 Jul;84(13):4465-9
references.pmid: 3474615